Edgewise net loss widens 58.74% to $57.33 million in Q2 FY26

Reuters2026/08/06 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Edgewise Therapeutics posted a GAAP net loss of $57.33 million, or $0.53 per share, for Q2 2026.
R&D expense climbed to $47.55 million from $33.56 million a year earlier, driven by higher clinical development activity and personnel costs.
G&A expense rose to $14.4 million from $9.05 million on higher personnel-related costs and increased professional fees.
Cash, cash equivalents and marketable securities totaled $460.71 million at June 30, excluding $1.55 billion upfront proceeds from the sevasemten sale.
Edgewise completed the Servier deal in July for $1.55 billion upfront, up to $2.65 billion total; it targets a Q4 2026 Phase 3 start for EDG-7500.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Edgewise net loss widens 58.74% to $57.33 million in Q2 FY26

You may also like

Crypto prices